MX2020008387A - Usos terapeuticos de agonistas glp1r. - Google Patents
Usos terapeuticos de agonistas glp1r.Info
- Publication number
- MX2020008387A MX2020008387A MX2020008387A MX2020008387A MX2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A MX 2020008387 A MX2020008387 A MX 2020008387A
- Authority
- MX
- Mexico
- Prior art keywords
- glp1r
- certain
- aspects
- disclosure provides
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los métodos para usar agonistas de receptor de péptido 1 similar al glucagón (GLP1R) se describen en general en la presente. En ciertos aspectos, la descripción proporciona métodos para tratar diabetes tipo 2 que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. En ciertos aspectos diferentes, la descripción proporciona métodos para tratar obesidad que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. En ciertos aspectos diferentes, la descripción proporciona métodos para disminuir hemoglobina glicada (por ejemplo, disminuir HbAlc} que incluyen administrar un agonista GLP1R de acuerdo con ciertos regímenes de dosis. Las composiciones que contienen agonistas GLP1R y su manufactura, por ejemplo, para uso como un medicamento también se describen en la presente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862668384P | 2018-05-08 | 2018-05-08 | |
PCT/US2019/030110 WO2019217165A1 (en) | 2018-05-08 | 2019-05-01 | Therapeutic uses of glp1r agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008387A true MX2020008387A (es) | 2020-12-11 |
Family
ID=66484210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008387A MX2020008387A (es) | 2018-05-08 | 2019-05-01 | Usos terapeuticos de agonistas glp1r. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210023072A1 (es) |
EP (1) | EP3790549A1 (es) |
JP (2) | JP2021523877A (es) |
KR (1) | KR20210005843A (es) |
AU (1) | AU2019266114A1 (es) |
CA (1) | CA3090823A1 (es) |
MX (1) | MX2020008387A (es) |
SG (1) | SG11202007966UA (es) |
TW (1) | TW202015683A (es) |
WO (1) | WO2019217165A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11702404B2 (en) | 2019-10-25 | 2023-07-18 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
US20230174546A1 (en) * | 2020-04-01 | 2023-06-08 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Crystalline form a of glp-1 receptor agonist and preparation method therefor |
US20230174547A1 (en) * | 2020-04-01 | 2023-06-08 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Pharmaceutically acceptable acid salt of free base of glp1 receptor agonist, and preparation method therefor |
EP4159722A4 (en) * | 2020-05-28 | 2024-06-26 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | METHOD FOR PREPARING GLP-1 RECEPTOR AGONIST |
US20230382921A1 (en) * | 2020-09-21 | 2023-11-30 | Vtv Therapeutics Llc | Amorphous Form of Isoquinoline Derivative |
WO2022109182A1 (en) | 2020-11-20 | 2022-05-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
CR20230495A (es) | 2021-04-21 | 2023-11-30 | Gilead Sciences Inc | Compuestos moduladores del glp-ir carboxibenzimidazólicos. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002534512A (ja) * | 1999-01-15 | 2002-10-15 | ノボ ノルディスク アクティーゼルスカブ | 非ペプチドglp−1アゴニスト |
BRPI0910282A2 (pt) | 2008-03-07 | 2015-09-01 | Transtech Pharma Inc | Composto oxadiazo-antraceno para o tratamento de diabetes |
AU2010232750B2 (en) | 2009-03-30 | 2015-10-29 | Vtv Therapeutics Llc | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof |
WO2011031620A1 (en) * | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
SG11201405353VA (en) * | 2012-03-22 | 2014-09-26 | Transtech Pharma Llc | Tris(hydroxymethyl)aminomethane salts of a small-molecule glp1r agonist and pharmaceutical compositions and uses thereof |
ES2687083T3 (es) * | 2013-01-17 | 2018-10-23 | Vtv Therapeutics Llc | Combinaciones de un agonista del GLPR1 y metformina y el uso de estos para el tratamiento de la diabetes tipo 2 y otros trastornos |
-
2019
- 2019-05-01 EP EP19723616.9A patent/EP3790549A1/en active Pending
- 2019-05-01 CA CA3090823A patent/CA3090823A1/en active Pending
- 2019-05-01 MX MX2020008387A patent/MX2020008387A/es unknown
- 2019-05-01 JP JP2020544255A patent/JP2021523877A/ja active Pending
- 2019-05-01 SG SG11202007966UA patent/SG11202007966UA/en unknown
- 2019-05-01 KR KR1020207026027A patent/KR20210005843A/ko unknown
- 2019-05-01 AU AU2019266114A patent/AU2019266114A1/en active Pending
- 2019-05-01 WO PCT/US2019/030110 patent/WO2019217165A1/en unknown
- 2019-05-07 TW TW108115702A patent/TW202015683A/zh unknown
-
2020
- 2020-10-13 US US17/069,453 patent/US20210023072A1/en active Pending
-
2024
- 2024-05-17 JP JP2024081189A patent/JP2024112903A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210005843A (ko) | 2021-01-15 |
SG11202007966UA (en) | 2020-11-27 |
JP2021523877A (ja) | 2021-09-09 |
US20210023072A1 (en) | 2021-01-28 |
WO2019217165A1 (en) | 2019-11-14 |
CA3090823A1 (en) | 2019-11-14 |
AU2019266114A1 (en) | 2020-08-27 |
EP3790549A1 (en) | 2021-03-17 |
TW202015683A (zh) | 2020-05-01 |
JP2024112903A (ja) | 2024-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008387A (es) | Usos terapeuticos de agonistas glp1r. | |
SA521431209B1 (ar) | مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1 | |
NZ732000A (en) | Gip and glp-1 co-agonist compounds | |
PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
MX2023008854A (es) | Agonistas del receptor acoplado a proteinas g (gpcr), composiciones farmaceuticas que los comprenden y metodos para su uso. | |
PH12017500761A1 (en) | Co-agonists of glucagon and glp-1 receptors | |
MX2023001980A (es) | Derivado de imidazol fusionado, metodo de preparacion y uso medico del mismo. | |
TN2015000053A1 (en) | Fusion proteins for treating a metabolic syndrome | |
MY191321A (en) | Glucagon and glp-1 co-agonists for the treatment of obesity | |
EA201001801A1 (ru) | Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения | |
EP3575314A3 (en) | Glucagon derivatives | |
MX2009013779A (es) | Uso de agonistas de tlr y/o interferonas tipo 1 para aliviar la toxicidad de los regimenes terapeuticos de agonistas de tnf-r. | |
MX2021015154A (es) | Composicion farmaceutica parenteral de agonista dual de glp1/2. | |
AU2019284019A1 (en) | Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions | |
PH12020500338A1 (en) | Acylated oxyntomodulin peptide analog | |
MX2015008555A (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
MX2023012465A (es) | Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea. | |
MX2022011089A (es) | Peptidos como agonistas selectivos del receptor de gip. | |
PH12021551243A1 (en) | Oxyntomodulin peptide analog formulations | |
MX2024000757A (es) | Variantes recombinantes de proteínas r-espondina y uso de las mismas. | |
WO2014193832A3 (en) | Glucagon-like peptide 1 (glp-1) receptor modulators and uses thereof in regulating blood glucose levels | |
MX2024004333A (es) | Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas. | |
MX2021012177A (es) | Usos terapeuticos de dulaglutida. | |
MX2024004398A (es) | Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas. | |
MX2022006599A (es) | Terapia de combinacion usando co-agonistas de glucagon y glp-1 para el tratamiento de la obesidad. |